Joseph Biederman1, Maura DiSalvo2, Ronna Fried3, K Yvonne Woodworth2, Itai Biederman2, Stephen V Faraone4. 1. Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Boston, Massachusetts; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts. Electronic address: jbiederman@partners.org. 2. Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Boston, Massachusetts. 3. Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Boston, Massachusetts; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts. 4. Department of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, New York; K.G. Jebsen Centre for Psychiatric Disorders, Department of Biomedicine, University of Bergen, Bergen, Norway.
Abstract
PURPOSE: The aim of the study was to help quantify the protective effects of stimulant treatment on important functional outcomes in attention-deficit/hyperactivity disorder (ADHD) using the number needed to treat (NNT) statistic and examine whether these effects are moderated by sex. METHODS: Subjects were derived from three independent samples, two similarly designed case-control, 10-year prospective follow-up studies of boys and girls with and without ADHD grown up and a cross-sectional randomized clinical trial of lisdexamfetamine on driving performance and behavior. For all studies, subjects were evaluated with structured diagnostic interviews. To measure psychopharmacologic treatment in the follow-up studies, we collected information about each subject's stimulant medication use, age at onset, and age at termination of treatment. Subjects in the driving study underwent two driving simulation assessments (premedication and after 6 weeks of treatment on lisdexamfetamine or placebo). For each outcome, we ran a logistic regression model that included an interaction between sex and treatment status. Lifetime rates were used to calculate the NNT statistic. We also calculated adjusted NNT statistics that accounted for sex, age, socioeconomic status, and family intactness. RESULTS: The NNTs were very low, ranging from 3 to 10. No interaction effects with sex were detected (all p > .05). The adjusted NNTs mostly remained the same with the exception of any substance use disorder, which increased after controlling for age. CONCLUSIONS: Stimulants have strong protective effects on functional outcomes in youth with ADHD that are not moderated by sex. These results support the critical importance of early identification and treatment of children with ADHD of both sexes.
PURPOSE: The aim of the study was to help quantify the protective effects of stimulant treatment on important functional outcomes in attention-deficit/hyperactivity disorder (ADHD) using the number needed to treat (NNT) statistic and examine whether these effects are moderated by sex. METHODS: Subjects were derived from three independent samples, two similarly designed case-control, 10-year prospective follow-up studies of boys and girls with and without ADHD grown up and a cross-sectional randomized clinical trial of lisdexamfetamine on driving performance and behavior. For all studies, subjects were evaluated with structured diagnostic interviews. To measure psychopharmacologic treatment in the follow-up studies, we collected information about each subject's stimulant medication use, age at onset, and age at termination of treatment. Subjects in the driving study underwent two driving simulation assessments (premedication and after 6 weeks of treatment on lisdexamfetamine or placebo). For each outcome, we ran a logistic regression model that included an interaction between sex and treatment status. Lifetime rates were used to calculate the NNT statistic. We also calculated adjusted NNT statistics that accounted for sex, age, socioeconomic status, and family intactness. RESULTS: The NNTs were very low, ranging from 3 to 10. No interaction effects with sex were detected (all p > .05). The adjusted NNTs mostly remained the same with the exception of any substance use disorder, which increased after controlling for age. CONCLUSIONS: Stimulants have strong protective effects on functional outcomes in youth with ADHD that are not moderated by sex. These results support the critical importance of early identification and treatment of children with ADHD of both sexes.
Authors: Joseph Biederman; Ronna Fried; Paul Hammerness; Craig Surman; Bruce Mehler; Carter R Petty; Stephen V Faraone; Carolyn Miller; Michelle Bourgeois; Benjamin Meller; Kathryn M Godfrey; Bryan Reimer Journal: J Psychiatr Res Date: 2012-01-24 Impact factor: 4.791
Authors: Joseph Biederman; Michael C Monuteaux; Eric Mick; Timothy E Wilens; Jessie A Fontanella; Katrina M Poetzl; Taralee Kirk; Joshua Masse; Stephen V Faraone Journal: Biol Psychiatry Date: 2005-09-09 Impact factor: 13.382
Authors: J Biederman; S Faraone; S Milberger; J Guite; E Mick; L Chen; D Mennin; A Marrs; C Ouellette; P Moore; T Spencer; D Norman; T Wilens; I Kraus; J Perrin Journal: Arch Gen Psychiatry Date: 1996-05
Authors: Yi Lu; Arvid Sjölander; Martin Cederlöf; Brian M D'Onofrio; Catarina Almqvist; Henrik Larsson; Paul Lichtenstein Journal: JAMA Psychiatry Date: 2017-08-01 Impact factor: 21.596
Authors: Joseph Biederman; Carter R Petty; Michael C Monuteaux; Ronna Fried; Deirdre Byrne; Tara Mirto; Thomas Spencer; Timothy E Wilens; Stephen V Faraone Journal: Am J Psychiatry Date: 2010-01-15 Impact factor: 18.112
Authors: J Biederman; S V Faraone; K Keenan; J Benjamin; B Krifcher; C Moore; S Sprich-Buckminster; K Ugaglia; M S Jellinek; R Steingard Journal: Arch Gen Psychiatry Date: 1992-09
Authors: Paul Lichtenstein; Linda Halldner; Johan Zetterqvist; Arvid Sjölander; Eva Serlachius; Seena Fazel; Niklas Långström; Henrik Larsson Journal: N Engl J Med Date: 2012-11-22 Impact factor: 91.245